ICLRNasdaqServices-Commercial Physical & Biological Research
ICON PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 27, 2026
$168.14−2.04 (-1.20%)
Close on Oct 19, 2026
- Market cap
- $13.01B
- P/E (TTM)
- 300.2
- Dividend yield
- –
ICON PLC revenue by segment
By business segment
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ireland | $878.39M | $761.36M | $745.50M | $801.77M | $902.03M | $734.34M | $841.55M | $627.43M | $627.50M | $607.29M | $652.11M | $582.84M | 42.6% | -2.6% |
| United States | $546.67M | $642.60M | $630.08M | $649.04M | $573.40M | $672.42M | $628.80M | $755.38M | $790.51M | $808.36M | $758.10M | $830.93M | 26.5% | -4.7% |
| Rest of Europe | $385.03M | $390.85M | $455.90M | $399.04M | $360.07M | $375.87M | $365.97M | $420.76M | $383.20M | $389.60M | $401.28M | $384.29M | 18.7% | +6.9% |
| Rest of World | $253.40M | $239.19M | $281.04M | $234.57M | $203.60M | $232.69M | $225.55M | $238.37M | $240.72M | $238.00M | $229.11M | $242.25M | 12.3% | +24.5% |
From the segment and revenue-disaggregation notes of ICON's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.